Mealey's (February 4, 2019, 11:04 AM EST) -- WASHINGTON, D.C. — The Federal Circuit U.S. Court of Appeals on Feb. 1 rejected a challenge to an adverse inter partes review (IPR) by the Patent Trial and Appeal Board, agreeing with the board that claims 1-13 of a reissue patent directed to treating epilepsy are patentable (Mylan Pharmaceuticals Inc., et al. v. Research Corporation Technologies Inc., Nos. 2017-2088, -2089, -2091, Fed. Cir., 2019 U.S. App. LEXIS 3282)....